Full Press Release Details
Pharmaceuticals Announces Pricing of Initial Public Offering
PARK, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company
focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering
of 3,600,000 shares of its common stock at a public offering price of $6.00 per share. All of the shares are being offered by
Eton. In addition, Eton has granted the underwriter a 45-day option to purchase an additional 540,000 shares of common stock at
the initial public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by
Eton, are expected to be approximately $21.6 million, excluding any proceeds from the exercise of the underwriter's option
to purchase additional shares. Eton's common stock has been approved for listing on the Nasdaq Global Market and is expected
to begin trading under the ticker symbol "ETON" on November 13, 2018. The proposed offering is expected to close on
November 15, 2018, subject to customary closing conditions.
National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), is acting as the sole underwriter
for the offering. The Liquid Venture Partners group at National Securities Corporation was responsible for sourcing and executing
The Securities and Exchange Commission declared a registration statement relating to these securities effective on November 9,
2018. Interested parties may obtain copies of the final prospectus relating to this offering from:
Securities Corporation
200 Vesey Street, 25th Floor
Attn: Marguerite O'Brien
Telephone: (212) 417-8164
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of such state or jurisdiction.
Eton Pharmaceuticals, Inc
Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing
the FDA's 505(b)(2) regulatory pathway. Eton has a diversified pipeline of high-value product candidates in various stages